We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
featured

Journal Scan / Research · July 19, 2021

Mortality Benefit of Rivaroxaban Plus Aspirin in Patients With Chronic Coronary or Peripheral Artery Disease

JACC: Journal of the American College of Cardiology

 

Additional Info

Disclosure statements are available on the authors' profiles:

JACC: Journal of the American College of Cardiology
Mortality Benefit of Rivaroxaban Plus Aspirin in Patients With Chronic Coronary or Peripheral Artery Disease
J Am Coll Cardiol 2021 Jul 06;78(1)14-23, JW Eikelboom, DL Bhatt, KAA Fox, J Bosch, SJ Connolly, SS Anand, A Avezum, SD Berkowitz, KRH Branch, GR Dagenais, C Félix, TJ Guzik, RG Hart, AP Maggioni, E Muehlhofer, M Sharma, O Shestakovska, S Yusuf

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading